

# Anti-Obesity Drugs: Market Research Report

<https://marketpublishers.com/r/AFE5927BCA1EN.html>

Date: January 2019

Pages: 143

Price: US\$ 5,450.00 (Single User License)

ID: AFE5927BCA1EN

## Abstracts

This report analyzes the worldwide markets for Anti-Obesity Drugs in US\$ Million.

The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2024. Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs. The report profiles 25 companies including many key and niche players such as -

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline Plc

Eisai Co., Ltd.

Novo Nordisk A/S

Rhythm Pharmaceuticals

VIVUS, Inc.

## Contents

### 1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

Quantitative Techniques & Analytics

Product Definitions and Scope of Study

### 2. INDUSTRY OVERVIEW

Obesity and Overweight Statistics

Obesity – A Prelude

Anti-Obesity Drugs: A Market Characterized by High Unmet Needs

Currently Available Anti-Obesity Medications

Select Currently Available Short-term and Long-term Anti-Obesity Medication

Select Off-Label Drugs for Obesity

Saxenda Commands the AOM Market, Newer Drugs to Provide Impetus to Market Growth

**Table 1.** Prescription Uptake of Branded Anti-Obesity Drugs in the US (2016&2017):  
Estimated Number of Prescriptions (Thousands) for Belviq, Contrave, Qsymia and  
Saxenda (includes corresponding Graph/Chart)

Semaglutide: Highest Potential in the AOM Pipeline

Setbacks of Past Drugs

Positive Road Ahead for Belviq

Relaunch of Xenical

Relaunch of Contrave

Reluctance among Patients, Physicians, and Payers Hurts Market Prospects

New Drug Development – High on the Agenda, Despite the Market Restraints

Anti-Obesity Drugs in Phase-III Clinical Trials: As of July 2018

Anti-Obesity Drugs in Phase-II Clinical Trials: As of July 2018

Anti-Obesity Drugs in Phase-I Clinical Trials: As of July 2018

Diabetes Drug Companies Attempt to Foray into the Anti-Obesity Drugs Space

Competitive Landscape

**Table 2.** Worldwide Anti-Obesity Drugs Market by Leading Player (2017): Market Share Breakdown of Value Sales for Novo Nordisk, Orexigen, Eisai, Vivus, and Others (includes corresponding Graph/Chart)

Novo Nordisk – The Leading Player in the Market

Novo Nordisk's Anti-Obesity Drugs in Pipeline

The United States – The Largest Obesity and Anti-Obesity Market

Europe – A Market with Vast Potential

Obesity Creeps Up in Developing Countries

### **3. GROWTH DRIVERS AND MARKET TRENDS**

Alarming Rise in Global Obesity Levels – The Major Growth Factor

Classification of BMI

**Table 3.** Global Obesity Epidemic: Percentage of Overweight, Obese, and Severely Obese Adults for 2014 & 2025 (includes corresponding Graph/Chart)

**Table 4.** Severely Obese Population (in Thousands) Worldwide by Country: 2014 & 2025 (includes corresponding Graph/Chart)

Exponential Increase in Urban Population

**Table 5.** Urban Population Worldwide in Thousands: 1950-2050P (includes corresponding Graph/Chart)

Rising Incidence of Chronic Diseases Associated with Obesity Drive the Market Expansion

**Table 6.** Global Annual Medical Cost of CVD in US\$ Billion: 2010, 2015, 2020, 2025, and 2030 (includes corresponding Graph/Chart)

**Table 7.** Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others

Growing Middle Class Population to Drive the Market Growth

**Table 8.** Global Middle Class Population (in Millions) and as a Percentage of Total Population: 2005, 2015, 2025 & 2035 (includes corresponding Graph/Chart)

**Table 9.** Global Middle Class Spending (in US\$ Trillion) by Geographic Region (2017E, 2025P & 2030P) (includes corresponding Graph/Chart)

Childhood Obesity – A Market with Unmet Needs

**Table 10.** Proportion of Overweight Children (Girls and Boys) in Total Population in Top 10 Countries with the Highest Overweight Children Population (includes corresponding Graph/Chart)

**Table 11.** US Proportion of Under Weight, Healthy Weight, Overweight and Obese Children in 10-13 Years Age Group (includes corresponding Graph/Chart)

Commercial Weight-Loss Companies Foray into the Market

Online Drug Stores Boost Sales

Barriers to Development of Effective Drugs

Regulatory Additions – A Barrier to Entry?

High Drug Development Costs – A Major Setback

Weight Loss Alternatives – A Market Dampener

#### **4. SELECT RESEARCH INITIATIVES**

Researchers Determine Molecular Structure of Neuropeptide Y1 Receptor

Researchers Develop new Antibody to Fight Obesity

Researchers Develop a New Drug that Reduce Fat Cells

NTU Scientists Develop a Microneedle Skin Patch

Researchers Explore Combination of Anti-Obesity Medicines for Enhanced Outcomes

#### **5. OBESITY - AN INTRODUCTION**

Understanding Fats

Obesity

Diagnosis of Obesity

BMI Calculation and Classification  
Waist Circumference and BMI  
Types of Obesity  
Monogenic Obesity  
Polygenic Obesity  
Causes of Obesity  
Unhealthy Eating Habits  
Environmental and Genetic Factors  
Sedentary Lifestyle  
Alcohol Intake  
Childhood Obesity  
Psychological Factors  
Pregnancy  
Hormonal Disorders  
Drugs  
Aging  
Risks Associated with Obesity  
Obesity Treatment  
Dietary Therapy  
Exercise Therapy  
Behavior Therapy  
Pharmacotherapy  
Weight Loss Surgery  
Invasive Vis-à-vis Non-invasive Procedures  
A Brief Review of Select Invasive Procedures  
Bariatric Surgery  
Laparoscopic Adjustable Gastric Banding (LAGB)  
Vertical Banded Gastroplasty (VBG)  
Roux-en-Y Gastric Bypass Procedure (RYGB)  
Lap-Band Procedure  
Gastric Band Procedure  
Gastric Bypass Procedure  
Doudenal Switch  
Prescription Drugs Vis-à-vis Non-Prescription Drugs

**Table 12.** Obesity Treatment Options and Corresponding Success Rate

## **6. ANTI-OBESITY DRUGS - AN INSIGHT**

Introduction  
Mechanism of Action  
Review of Available Prescription Anti-Obesity Drugs  
Phentermine  
Orlistat  
Belviq (Lorcaserin)  
Phentermine/Topiramate  
Contrave  
Saxenda

## **7. COMPETITIVE LANDSCAPE**

### 7.1 Focus on Select Global Players

F. Hoffmann-La Roche Ltd. (Switzerland)  
GlaxoSmithKline Plc. (UK)  
Eisai Co., Ltd. (Japan)  
Novo Nordisk A/S (Denmark)  
Rhythm Pharmaceuticals (USA)  
VIVUS, Inc. (USA)

### 7.2 Recent Industry Activity

Kallyope and Novo Nordisk Collaborate to Develop Novel Therapeutics for Diabetes and Obesity  
Orexigen Completes the Sale of Contrave to Pernix  
CohBar Presents Preclinical Data of CB4211 at the American Diabetes Association  
CohBar Presents Preclinical Data of CB4209/CB4211 Program at the AASLD Liver Meeting  
Novo Nordisk Launches Anti-obesity Drug in India  
Orexigen Therapeutics in Partnership with Laboratorios Farmaceuticos Rovi, S. A. Launches Mysimba in Spain  
Eisai Acquires Global Rights for Developing and Marketing Belviq from Arena  
Alvogen Partners with Vivus to Regulate, Sell, and Market Qsymia in the Republic of Korea  
Boehringer Ingelheim Collaborate with Gubra to Develop Novel Peptide Compounds for Treating Obesity  
Orexigen Therapeutics Agrees with Merck for Commercializing and Distributing Contrave in Latin America  
VIVUS Enters into an Agreement with Alvogen to Market Qsymia(R) in the Republic of Korea

Orexigen Enters into Agreement with Cheplapharm to Distribute Mysimba in Austria, France, and Germany

Orexigen Expands Agreement with Biologix FZCO for Contrave in the Middle East, with inclusion of Egypt

Novo Nordisk Plans to Enter Latin America for Selling Anti-Obesity Drugs

Rhythm Expands Setmelanotide's Phase 2 Clinical Trials to Treat Bardet-Biedl Syndrome Obesity

Rhythm Receives Expanded FDA Breakthrough Therapy Designation for Setmelanotide to Treat Rare Genetic Obesity Disorders

Orexigen Therapeutics Enters into Commercialization and Distributorship Agreement with Navamedic ASA for Mysimba in Five Nordic Countries

Orexigen Therapeutics Submits Contrave® to Health Canada for Marketing Approval

Orexigen Therapeutics Enters into Commercialization and Distributorship Agreement with Bruno Farmaceutici S. p. A. for Mysimba in Italy

Eisai Co., Ltd. Acquires All Rights of BELVIQ from Arena Pharmaceuticals, Inc. for Developing and Marketing

BELVIQ, an anti-obesity agent, Receives Approval in Brazil

Orexigen Therapeutics Enters into Commercialization and Distributorship Agreement with Biologix FZCO to Distribute Contrave in the Middle East

Orexigen Therapeutics Enters into Agreement with Consilient Health Ltd. for Distributing and Commercializing Mysimba in Ireland and the UK

Orexigen Therapeutics Agrees with Valeant to Distribute and Commercialize Contrave in New Zealand and Australia

Orexigen Therapeutics Enters into Commercialization and Distributorship Agreement with Valeant Canada for Contrave

Orexigen Therapeutics Enters into Agreement with Laboratorios Farmaceuticos Rovi, S. A. to Commercialize and Distribute Mysimba in Spain

Orexigen Completes the Acquisition of All U. S. Rights to Contrave

Eisai's announces the Approval of Lorcaserin in Mexico

Orexigen Receives Approval for Contrave in South Korea

Orexigen and Valeant Pharmaceuticals Team up to Commercialize and Distribute Mysimba in Europe and Turkey

Eisai Announces the Availability of BELVIQ XR in the United States

## 8. GLOBAL MARKET PERSPECTIVE

**Table 13.** World Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Geographic Region/Country - US, Canada, Europe, Asia-Pacific, Latin America and

Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart)

**Table 14.** World 10-Year Perspective for Anti-Obesity Drugs by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2015, 2018 and 2024 (includes corresponding Graph/Chart)

## 9. REGIONAL MARKET PERSPECTIVE

### 9.1 The United States

#### A. Market Analysis

Obesity Prevalence and Incidence Statistics

The US Anti-Obesity Drugs Market: A Review

**Table 15.** The US Anti-Obesity Drugs Market by Leading Player (2017): Market Share Breakdown of Value Sales for Novo Nordisk, Orexigen, Eisai, Vivus, and Others (includes corresponding Graph/Chart)

Childhood Obesity – Catching Them Young

Key Obesity Statistics: Opportunity Indicator

**Table 16.** Prevalence of Obesity in the US among Population aged 20 and Above, by Sex and Age (2015-2016) (includes corresponding Graph/Chart)

**Table 17.** Obesity Prevalence in the US among the population aged between 2 to 19 years, by Sex (2015-2016) (includes corresponding Graph/Chart)

**Table 18.** Trends in Obesity Prevalence among Population aged 20 and Over and Youth aged in between 2 and 19 Years in the US (2009-2016) (includes corresponding Graph/Chart)

Top Ranked States in the US based on Fatness, Obesity, and Overweight

Regulatory Environment

High Development Costs – A High Entry Barrier for Drug Makers

Obesity and Related Ailments: Burden on Societal and Economic Costs

B. Market Analytics



**Table 19.** The US Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart)

## 9.2 Canada

### A. Market Analysis

Novo Nordisk's Saxenda Weight-Loss Medication Awaits Approval in Canada (2018)

### B. Market Analytics

**Table 20.** Canadian Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart)

## 9.3 Europe

### A. Market Analysis

Europe – An Opportune Market for Weight Management Drugs

### B. Market Analytics

**Table 21.** European Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Geographic Region/Country - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart)

**Table 22.** European 10-Year Perspective for Anti-Obesity Drugs by Geographic Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2018 and 2024 (includes corresponding Graph/Chart)

### 9.4.1 France

#### A. Market Analysis

Changing Lifestyle Alters Health Profile

#### B. Market Analytics

**Table 23.** French Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market

Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2024  
(includes corresponding Graph/Chart)

#### 9.4.2 Germany

##### A. Market Analysis

The Largest Anti-Obesity Market in Europe

##### B. Market Analytics

**Table 24.** German Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2024  
(includes corresponding Graph/Chart)

#### 9.4.3 Italy

##### Market Analysis

**Table 25.** Italian Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2024  
(includes corresponding Graph/Chart)

#### 8.4.4 The United Kingdom

##### A. Market Analysis

Anti-Obesity Drugs – the Need of the Hour as NHS Firefights Rising Peril of Obesity

##### B. Market Analytics

**Table 26.** The UK Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2024  
(includes corresponding Graph/Chart)

#### 9.4.5 Rest of Europe

##### A. Market Analysis

##### Review of Select Markets

Spain

Belgium

The Netherlands

Finland

Sweden

## B. Market Analytics

**Table 27.** Rest of European Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart)

### 9.5 Asia-Pacific

#### A. Market Analysis

##### Brief Review of Select Countries

Australia

China

India

Korea

Use of Diet Pills Lack Proper Monitoring

New Zealand

#### B. Market Analytics

**Table 28.** Asia-Pacific Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart)

### 9.6 Latin America

#### A. Market Analysis

Mexico – A Review

#### B. Market Analytics

**Table 29.** Latin American Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart)

### 9.7 Rest of World

#### Market Analysis

**Table 30.** Rest of World Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2024

(includes corresponding Graph/Chart)

## **10. COMPANY PROFILES**

Total Companies Profiled:

The United States (9)

Japan (2)

Europe (8)

Germany (1)

The United Kingdom (1)

Italy (1)

Rest of Europe (5)

Asia-Pacific (Excluding Japan) (6)

## I would like to order

Product name: Anti-Obesity Drugs: Market Research Report

Product link: <https://marketpublishers.com/r/AFE5927BCA1EN.html>

Price: US\$ 5,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AFE5927BCA1EN.html>